CTMX Stock Summary

• Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 11.42% of US stocks have a lower such ratio.
• Over the past twelve months, CTMX has reported earnings growth of 92.22%, putting it ahead of 88.62% of US stocks in our set.
• Revenue growth over the past 12 months for CytomX Therapeutics Inc comes in at -19.2%, a number that bests just 10.03% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to CytomX Therapeutics Inc, a group of peers worth examining would be BCRX, ATHX, WVE, KALV, and RCUS.
• Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.